While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.
With the EUA, LabCorp is able to sell the test kit directly to consumers without a prescription, making it the first over-the-counter COVID-19 test in the US.
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
The agreement will initially focus on making available assays developed and validated by LabCorp's Covance business, with the first assays targeting oncology.
